The Claim
Insufficient cumulative LDL treatment-years explain the failure of some LDL-lowering trials to reduce cardiovascular events, indicating that treatment duration and intensity are critical determinants of cardiovascular outcomes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Longer and more intense LDL-lowering treatment is required to reduce cardiovascular events, and trials that failed to show benefit did so because the treatment was not given long enough or strongly enough.
See the scientific wording
The failure of some LDL-lowering trials to reduce cardiovascular events may be explained by insufficient cumulative LDL treatment-years, rather than lack of drug efficacy, suggesting that treatment duration and intensity are critical determinants of outcome.
When LDL cholesterol stays low for a long time, fatty deposits in artery walls stop growing and become harder and less likely to rupture. This stops blood clots from forming and prevents heart attacks and strokes.
What the research says
1 studyStudy: LDL treatment-years: a new paradigm for cardiovascular risk reduction
This study found that cholesterol-lowering drugs only start working well after you’ve taken them long enough and at high enough doses to build up a certain total amount of LDL reduction. Past trials that didn’t work didn’t give people enough time or strong enough doses to reach this magic number.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.